MINSTRY-SCINCE-ICT-FUTUR
17.5.2017 09:02:11 CEST | Business Wire | Press release
31 promising Korean startups are attending TNW Conference Europe 2017 (hereafter “the Conference”) to be held May 18-19, 2017, in Amsterdam, Netherlands.
31 Promising startups of Korea will showcase advanced technologies such as Fintech based on blockchain, nano new materials, eco-friendly products, IoT and software service to the European market.
Ministry of Science, ICT and Future Planning (hereafter “MSIP”), Ministry of Culture, Sports & Tourism and Small and Medium Business Administration of the Korean government are making joint efforts in backing tech startups to advance into the European market under the name of K-Startup.
Mr. Koh Kyeongmo, Deputy Minister for Creative Economy Coordination in MSIP showed high expectations for the Conference in that it will trigger promotion of Korean startups’ tech capabilities on the global stage and attract substantial investment in the future.
TNW Conference Europe 2017
This is the largest tech conference in Europe having been initiated from 2006 and it consists of programs including workshops, tailored networking events for startups and exhibitions. It is expected to attract about 20,000 participants and 4,000 companies who are tech investors, accelerators and startups from over 100 countries.
The Korean government will increase the support for Korean tech startups pioneering into the European market by utilizing the venue of the Conference.
Korea in TNW Conference
In the Conference, the Korean government is operating K-Startup Pavilion which displays products and services from various fields such as iris recognition devices and solutions, drones with one-handed controllers, seed packages and portable hydro-power generators.
In particular, the Korean government will cohost Investor Dinner with TNW, thereby fostering networking of global investors. In the venue, around 80 promising investors handpicked by TNW along with some Korean startups participate.
Furthermore, 7 Korean startups are advancing to the semi-final round of competition which guarantees them the chance to pitch in Arena. In the competitions, Korean startups’ innovative products will be promoted and the startups will compete to be award-winners.
31 Promising Startups of Korea
Major Korean startups will take part in the Conference. For example, Smart Study , a kids-content startup having exceeded 15.5m dollars in sales as of 2016 will attend the event. Studio XID , a software startup of which its service is used by global companies such as Google, Facebook, Baidu and Alipay will also participate. For detailed information on best Korean startups, please visit here or watch K-Startup Show reel.
- Smart Study: www.smartstudy.co.kr
- Studio XID: www.protopie.io
- KOREA STARTUPS: http://thewelcome.ipdisk.co.kr/publist/VOL1/guest/Korea%20Startup%20IR%20Report%20Edition.pdf
- K-Startup Show reel: http://thewelcome.ipdisk.co.kr:80/publist/VOL1/guest/K_Startup_TNW%20Showreel.mp4
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005049/en/
Contact:
Ministry of Science, ICT and Future Planning
Yang Yunay, +82 2 2110
2086
Deputy Director
yunay@korea.kr
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom